Brent K Hollenbeck1, Mary Oerline2, Samuel R Kaufman2, Megan E V Caram3, Stacie B Dusetzina4, Andy M Ryan5, Vahakn B Shahinian6. 1. Departments of Urology, University of Michigan, Ann Arbor, MI. Electronic address: bhollen@med.umich.edu. 2. Departments of Urology, University of Michigan, Ann Arbor, MI. 3. Medicine, University of Michigan, Ann Arbor, MI. 4. Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN. 5. Health Management and Policy, University of Michigan, Ann Arbor, MI. 6. Departments of Urology, University of Michigan, Ann Arbor, MI; Medicine, University of Michigan, Ann Arbor, MI.
Abstract
OBJECTIVE: To measure the association between market-level promotional payments to urologists by the manufacturers of abiraterone and enzalutamide and national prescribing patterns. METHODS: A 20% national sample of the 2015 Part D event file was used to identify patients filling their first prescription for abiraterone and enzalutamide and their prescribing physicians. The 2015 Open Payments data were used to characterize promotional payments made to physicians at the market level. Generalized linear models were then used to measure the relationship between market-level payments to urologists and the physician specialty prescribing abiraterone or enzalutamide for the first time RESULTS: In 2015, 2318 men filled a prescription for abiraterone or enzalutamide by a urologist or medical oncologist. Increasing market-level promotional payments to urologists for abiraterone or enzalutamide was strongly associated with a urologist prescribing either drug-24.3% versus 5.8% of those residing in the markets with highest and lowest level of promotional payments to urologists, respectively (P <.01). Neither the number of urologists residing in a market nor other promotional payment measures (ie, to medical oncologists for these drugs, or to all physicians for all other drugs) were associated with a urologist prescribing either drug. CONCLUSION: Promotional payments to urologists at the market level are strongly associated with the specialty of the physician prescribing abiraterone or enzalutamide for the first time. Future work should elucidate the effects of the shift in prescribing patterns on quality of care and financial hardship for men with advanced prostate cancer.
OBJECTIVE: To measure the association between market-level promotional payments to urologists by the manufacturers of abiraterone and enzalutamide and national prescribing patterns. METHODS: A 20% national sample of the 2015 Part D event file was used to identify patients filling their first prescription for abiraterone and enzalutamide and their prescribing physicians. The 2015 Open Payments data were used to characterize promotional payments made to physicians at the market level. Generalized linear models were then used to measure the relationship between market-level payments to urologists and the physician specialty prescribing abiraterone or enzalutamide for the first time RESULTS: In 2015, 2318 men filled a prescription for abiraterone or enzalutamide by a urologist or medical oncologist. Increasing market-level promotional payments to urologists for abiraterone or enzalutamide was strongly associated with a urologist prescribing either drug-24.3% versus 5.8% of those residing in the markets with highest and lowest level of promotional payments to urologists, respectively (P <.01). Neither the number of urologists residing in a market nor other promotional payment measures (ie, to medical oncologists for these drugs, or to all physicians for all other drugs) were associated with a urologist prescribing either drug. CONCLUSION: Promotional payments to urologists at the market level are strongly associated with the specialty of the physician prescribing abiraterone or enzalutamide for the first time. Future work should elucidate the effects of the shift in prescribing patterns on quality of care and financial hardship for men with advanced prostate cancer.
Authors: Oliver Sartor; Emuella Flood; Kathleen Beusterien; Josephine Park; Iain Webb; David MacLean; Bruce J O Wong; H Mark Lin Journal: Clin Genitourin Cancer Date: 2014-08-19 Impact factor: 2.872
Authors: Ethan Basch; Karen Autio; Charles J Ryan; Peter Mulders; Neal Shore; Thian Kheoh; Karim Fizazi; Christopher J Logothetis; Dana Rathkopf; Matthew R Smith; Paul N Mainwaring; Yanni Hao; Thomas Griffin; Susan Li; Michael L Meyers; Arturo Molina; Charles Cleeland Journal: Lancet Oncol Date: 2013-09-25 Impact factor: 41.316
Authors: June M McKoy; E Allison Lyons; Eniola Obadina; Kenneth Carson; A Simon Pickard; Paul Schellhammer; David McLeod; Cynthia E Boyd; Norene McWilliams; Oliver Sartor; Glen T Schumock; Kathryn McCaffery; Charles L Bennett Journal: J Clin Oncol Date: 2005-12-01 Impact factor: 44.544
Authors: Christina W Lee; C Ann Vitous; Maria J Silveira; Jane Forman; Lesly A Dossett; Lona Mody; Justin B Dimick; Pasithorn A Suwanabol Journal: J Pain Symptom Manage Date: 2019-02-10 Impact factor: 5.576
Authors: Karim Fizazi; Howard I Scher; Kurt Miller; Ethan Basch; Cora N Sternberg; David Cella; David Forer; Mohammad Hirmand; Johann S de Bono Journal: Lancet Oncol Date: 2014-08-04 Impact factor: 41.316
Authors: Pasithorn A Suwanabol; Ari C Reichstein; Z Tuba Suzer-Gurtekin; Jane Forman; Maria J Silveira; Lona Mody; Arden M Morris Journal: J Palliat Med Date: 2018-03-13 Impact factor: 2.947
Authors: Stephen Harland; John Staffurth; Arturo Molina; Yanni Hao; Dennis D Gagnon; Cora N Sternberg; David Cella; Karim Fizazi; Christopher J Logothetis; Thian Kheoh; Christopher M Haqq; Johann S de Bono; Howard I Scher Journal: Eur J Cancer Date: 2013-08-22 Impact factor: 9.162
Authors: Lillian Y Lai; Mary K Oerline; Samuel R Kaufman; Lindsey A Herrel; Ted A Skolarus; Stacie B Dusetzina; Chad Ellimoottil; Vahakn B Shahinian; Brent K Hollenbeck; Megan E V Caram Journal: Urology Date: 2021-12-01 Impact factor: 2.649